Literature DB >> 20610850

A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy.

Jian Z Wang1, Zhibin Huang, Simon S Lo, William T C Yuh, Nina A Mayr.   

Abstract

Conventional radiation therapy for cancer usually consists of multiple treatments (called fractions) with low doses of radiation. These dose schemes are planned with the guidance of the linear-quadratic (LQ) model, which has been the most prevalent model for designing dose schemes in radiation therapy. The high-dose fractions used in newer advanced radiosurgery, stereotactic radiation therapy, and high-dose rate brachytherapy techniques, however, cannot be accurately calculated with the traditional LQ model. To address this problem, we developed a generalized LQ (gLQ) model that encompasses the entire range of possible dose delivery patterns and derived formulas for special radiotherapy schemes. We show that the gLQ model can naturally derive the traditional LQ model for low-dose and low-dose rate irradiation and the target model for high-dose irradiation as two special cases of gLQ. LQ and gLQ models were compared with published data obtained in vitro from Chinese hamster ovary cells across a wide dose range [0 to approximately 11.5 gray (Gy)] and from animals with dose fractions up to 13.5 Gy. The gLQ model provided consistent interpretation across the full dose range, whereas the LQ model generated parameters that depended on dose range, fitted only data with doses of 3.25 Gy or less, and failed to predict high-dose responses. Therefore, the gLQ model is useful for analyzing experimental radiation response data across wide dose ranges and translating common low-dose clinical experience into high-dose radiotherapy schemes for advanced radiation treatments.

Entities:  

Mesh:

Year:  2010        PMID: 20610850     DOI: 10.1126/scitranslmed.3000864

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  41 in total

Review 1.  Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.

Authors:  Nitin Ohri; Adam P Dicker; Yaacov Richard Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-19       Impact factor: 7.038

2.  Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.

Authors:  Robert F Hobbs; Roger W Howell; Hong Song; Sébastien Baechler; George Sgouros
Journal:  Radiat Res       Date:  2014-01       Impact factor: 2.841

3.  Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes.

Authors:  Brian D Kavanagh
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

4.  Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen.

Authors:  Krishan R Jethwa; Sean S Park; Karthik Gonuguntla; Stephanie M Wick; Laura A Vallow; Christopher L Deufel; Thomas J Whitaker; Keith M Furutani; Kathryn J Ruddy; Kimberly S Corbin; Tina J Hieken; Robert W Mutter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-21       Impact factor: 7.038

Review 5.  Indirect cell death and the LQ model in SBRT and SRS.

Authors:  Chang W Song; Stephanie Terezakis; Bahman Emami; Robert J Griffin; Paul W Sperduto; Mi-Sook Kim; L Chinsoo Cho
Journal:  J Radiosurg SBRT       Date:  2020

6.  Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC.

Authors:  John P Kirkpatrick; Lawrence B Marks; Charles S Mayo; Yaacov R Lawrence; Niranjan Bhandare; Samuel Ryu
Journal:  J Radiosurg SBRT       Date:  2011

7.  SBRT for lung oligometastases: Who is the perfect candidate?

Authors:  Pierina Navarria; Fiorenza De Rose; Anna Maria Ascolese
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-30

8.  High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck.

Authors:  Sewit Teckie; Benjamin H Lok; Shyam Rao; Stanley I Gutiontov; Yoshiya Yamada; Sean L Berry; Michael J Zelefsky; Nancy Y Lee
Journal:  Oral Oncol       Date:  2016-07-12       Impact factor: 5.337

9.  Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.

Authors:  Jill Gallaher; Leah M Cook; Shilpa Gupta; Arturo Araujo; Jasreman Dhillon; Jong Y Park; Jacob G Scott; Julio Pow-Sang; David Basanta; Conor C Lynch
Journal:  Clin Exp Metastasis       Date:  2014-08-31       Impact factor: 5.150

Review 10.  Stereotactic body radiotherapy treatment of extracranial metastases.

Authors:  Joseph K Salama; John P Kirkpatrick; Fang-Fang Yin
Journal:  Nat Rev Clin Oncol       Date:  2012-09-25       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.